IL-2 Immunotherapy Fails To Benefit HIV-infected Individuals Already Taking Antiretrovirals

Friday, February 20, 2009 - 23:28 in Health & Medicine

Providing a synthetic form of the immune system protein interleukin-2 to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net